VJHemOnc Podcast COSTEM: the role of alloHSCT in ALL
Oct 25, 2021
The podcast discusses the evolving landscape of ALL treatment, including TK inhibitors and bispecific antibodies. It debates the relevance of alloHSCT in the current therapeutic landscape. The chapter explores the decision-making process for treating ALL patients and the challenges posed by CAR T cells. It also discusses therapy regimens without transplantation for Philadelphia Positive ALL patients and debates the potential avoidance of transplant in the elderly population. Additionally, a study on the use of dasatinib and blinotomer in treating ALL is discussed, showcasing high remission rates and potential for long-term remission without transplantation.
Chapters
Transcript
Episode notes